MX2022006751A - Minitrampas de vegf y metodos de uso de las mismas. - Google Patents

Minitrampas de vegf y metodos de uso de las mismas.

Info

Publication number
MX2022006751A
MX2022006751A MX2022006751A MX2022006751A MX2022006751A MX 2022006751 A MX2022006751 A MX 2022006751A MX 2022006751 A MX2022006751 A MX 2022006751A MX 2022006751 A MX2022006751 A MX 2022006751A MX 2022006751 A MX2022006751 A MX 2022006751A
Authority
MX
Mexico
Prior art keywords
traps
methods
vegf mini
mini
vegf
Prior art date
Application number
MX2022006751A
Other languages
English (en)
Inventor
Samuel Davis
Amy Johnson
Shawn Lawrence
Andrew Tustian
Joel Martin
Ning Li
Shunhai Wang
Ankit Vartak
Meghan Casey
Jaimie Mastrogiacomo
Matthew Franklin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022006751A publication Critical patent/MX2022006751A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona moléculas de minitrampa de VEGF y un método para tratar o prevenir trastornos angiogénicos tal como trastornos oculares angiogénicos y cáncer.
MX2022006751A 2019-12-06 2020-12-04 Minitrampas de vegf y metodos de uso de las mismas. MX2022006751A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
PCT/US2020/063238 WO2021113591A1 (en) 2019-12-06 2020-12-04 Vegf mini-traps and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022006751A true MX2022006751A (es) 2022-08-19

Family

ID=74046173

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006751A MX2022006751A (es) 2019-12-06 2020-12-04 Minitrampas de vegf y metodos de uso de las mismas.

Country Status (13)

Country Link
US (1) US20230063116A1 (es)
EP (1) EP4069264A1 (es)
JP (1) JP2023505216A (es)
KR (1) KR20220110555A (es)
CN (1) CN114786695A (es)
AU (1) AU2020397053A1 (es)
BR (1) BR112022010686A2 (es)
CA (1) CA3163876A1 (es)
CL (1) CL2022001479A1 (es)
CO (1) CO2022008799A2 (es)
IL (1) IL293286A (es)
MX (1) MX2022006751A (es)
WO (1) WO2021113591A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
UA74146C2 (uk) 1999-06-08 2005-11-15 Редженерон Фармасьютікалс, Інк. Модифікований хімеричний поліпептид з покращеними фармакокінетичними властивостями
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) * 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
KR20210030510A (ko) 2011-01-13 2021-03-17 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
WO2018147960A1 (en) * 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .

Also Published As

Publication number Publication date
WO2021113591A1 (en) 2021-06-10
JP2023505216A (ja) 2023-02-08
IL293286A (en) 2022-07-01
CN114786695A (zh) 2022-07-22
US20230063116A1 (en) 2023-03-02
CO2022008799A2 (es) 2022-06-30
KR20220110555A (ko) 2022-08-08
EP4069264A1 (en) 2022-10-12
BR112022010686A2 (pt) 2022-08-23
CL2022001479A1 (es) 2023-01-20
AU2020397053A1 (en) 2022-06-23
CA3163876A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
MX2022013526A (es) Degradadores de proteinas y usos de los mismos.
MX2023006467A (es) Oligonucleotidos de conmutacion o modulacion de empalme de pre-arnm que comprenden radicales de andamio biciclicos, con caracteristicas mejoradas para el tratamiento de trastornos geneticos.
MD3804737T2 (ro) Compoziții care conțin tulpini bacteriene
MY195720A (en) Transthyretin (Ttr) Irna Compositions and Methods of Use Thereof for Treating or Preventing Ttr-Associated Diseases
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
MX2018010292A (es) Tratamiento de condiciones oculares alergicas con ciclodextrinas.
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2019001718A (es) Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
WO2020021477A3 (en) Compositions and methods for treating the eye
CY1124699T1 (el) Ενωσεις
MX2020006297A (es) Variantes de cd19.
AU2018205275B2 (en) Methods for the treatment of neurological disorders
MX2021003903A (es) Terapia combinada para el melanoma.
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
PH12018502318A1 (en) Compositions and methods for treatment of inflammation of infection of the eye
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.